Electrical wavefront fusion in heart failure patients with LBBB and CRT: implications for optimization.

Journal of Electrocardiology 2020

View Full Publication

Electrical wavefront fusion in heart failure patients with left bundle branch block and cardiac resynchronization therapy: Implications for optimization


Alan J. Bank MD, Ryan M. Gage MS, Antonia E. Schaefer PhD, Kevin V. Burns PhD, Christopher D. Brown BA


Abstract


Background


Novel metrics of electrical dyssynchrony based on multi-electrode mapping and ECG-based markers of fusion are better predictors of cardiac resynchronization therapy (CRT) response than QRS duration.


Objective


To describe a new methodology for measuring electrical synchrony based on wavefront fusion and electrocardiographic cancellation in patients with CRT and its potential for CRT optimization.


Methods


Patients with left bundle branch block (LBBB) type conduction and CRT (n = 84) were studied at multiple device settings using an ECG belt (53 anterior and posterior electrodes). The area between combinations of anterior and posterior curves (AUC) was calculated and cardiac resynchronization index (CRI) defined as percent change in AUC compared to LBBB.


Results


In 14 patients with complete heart block or atrial fibrillation, CRI at optimal ventriculo-ventricular delay (VVD) (40 ± 19 ms) was significantly higher than with simultaneous biventricular pacing (BiVp) (90 ± 8.6% vs. 54.2 ± 24.2%, p < 0.001). In all 70 patients paced LV-only, LV-paced wavefront was ahead of native wavefront at short atrio-ventricular delay (AVD) and CRI increased with increase in AVD, peaked, and then decreased. Optimal CRI during LV-only pacing was significantly better than optimal CRI with simultaneous BiVp (89.6 ± 8% vs. 64.4 ± 22%, p < 0.001), and occurred at AVD 68 ± 22 ms less than the atrial-RV sensed interval. With sequential BiVp, best CRI was 83.9 ± 13% (with LV preactivation of 40 ± 20 ms). Best CRI at any setting was markedly better than CRI at standard setting (91.6 ± 7.7% vs. 52.7 ± 23.3, p < 0.001).


Conclusions


We describe a novel non-invasive investigational tool that quantifies wavefront fusion and electrical dyssynchrony, and may allow for individualized CRT optimization.


Keywords: Cardiac resynchronization therapy; Electrical dyssynchrony; Optimization; Wavefront fusion; Wavefront cancellation; Electrocardiography

Elevate heart failure therapy for all CRT patients.

Connect to explore engaging with Myochron on its journey to help patients, providers, and health systems elevate the standard of care, while reducing the burden of non-response.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.